Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedAdrenal cortex carcinoma was added as a lay term for Adrenocortical Carcinoma in the Conditions section.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; the page now shows Revision: v3.4.3.SummaryDifference0.0%

- Check67 days agoChange DetectedThe footer now displays Revision: v3.4.2, replacing Revision: v3.4.1.SummaryDifference0.0%

- Check75 days agoChange DetectedA minor revision update was added (Revision: v3.4.1) and the previous revision (v3.4.0) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.